• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/12/21 3:21:37 PM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email
    SC 13G 1 ea135345-13gzhijun_anpac.htm SCHEDULE 13G
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. ___)*

     

    AnPac Bio-Medical Science Co., Ltd.
    (Name of Issuer)
     

    Class A Ordinary Shares

    Class B Ordinary Shares

    (Title of Class of Securities)
     

    Class A Ordinary Shares: G0393E107

    Class B Ordinary Shares: N/A

    (CUSIP Number)
     
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐  Rule 13d-1(b)
       
      ☐  Rule 13d-1(c)
       
      ☒  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. Class A: G0393E107; Class B: N/A  

     

    1 Names of Reporting Persons

    Feng Guo

    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒
    3 Sec Use Only

     

    4

    Citizenship or Place of Organization

    China

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5

    Sole Voting Power

    0
    6 Shared Voting Power

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares (1)

    7

    Sole Dispositive Power

    0
    8 Shared Dispositive Power

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    ☐
    11 Percent of class represented by amount in row (9)

    6.60% of Class A Ordinary Shares

    8.66% of Class B Ordinary Shares 

    12

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Mr. Feng Guo is the controlling shareholder and a member of the three-person investment committee of Jiaxing Zhijun Investment Management Co., Ltd, which is the general partner of Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership). Zhijun Sihang Holding Limited, a British Virgin Islands company, is wholly-owned by Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership) and holds 536,000 Class A ordinary shares and 247,900 Class B ordinary shares. In addition, Lei Luo holds 70,700 Class A ordinary shares for the benefit of Zhijun Sihang Holdings Limited.

     

    (3)The calculations in the table below are based on 12,055,760 ordinary shares (including 9,192,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

    Page 2 of 12

     

     

    SCHEDULE 13G

     

    CUSIP No. Class A: G0393E107; Class B: N/A  

     

    1

    Names of Reporting Persons

    Zhijun Sihang Holding Limited
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒
    3

    Sec Use Only

     
    4

    Citizenship or Place of Organization

    British Virgin Islands

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    6

    Shared Voting Power

    606,700 shares of Class A Ordinary Shares
    7 Sole Dispositive Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    8

    Shared Dispositive Power

    606,700 shares of Class A Ordinary Shares

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    ☐
    11 Percent of class represented by amount in row (9)

    6.60% of Class A Ordinary Shares

    8.66% of Class B Ordinary Shares 

    12

    Type of Reporting Person (See Instructions)

    HC

      

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Zhijun Sihang Holding Limited, a British Virgin Islands company, holds 536,000 Class A ordinary shares and 247,900 Class B ordinary shares. In addition, Lei Luo holds 70,700 Class A ordinary shares for the benefit of Zhijun Sihang Holdings Limited.  Zhijun Sihang Holding Limited is a wholly-owned subsidiary by Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership). Jiaxing Zhijun Investment Management Co., Ltd. is the general partner of Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership) and Mr. Feng Guo is the controlling shareholder and a member of the three-person investment committee of Jiaxing Zhijun Investment Management Co., Ltd.

     

    (3)The calculations in the table below are based on 12,055,760 ordinary shares (including 8,692,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

    Page 3 of 12

     

     

    SCHEDULE 13G

     

    CUSIP No. Class A: G0393E107; Class B: N/A  

     

    1

    Names of Reporting Persons

    Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership)
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒
    3

    Sec Use Only

     
    4

    Citizenship or Place of Organization

    China

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    6

    Shared Voting Power

    606,700 shares of Class A Ordinary Shares
    7 Sole Dispositive Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    8

    Shared Dispositive Power

    606,700 shares of Class A Ordinary Shares

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    ☐
    11 Percent of class represented by amount in row (9)

    6.60% of Class A Ordinary Shares

    8.66% of Class B Ordinary Shares 

    12

    Type of Reporting Person (See Instructions)

    HC

      

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Zhijun Sihang Holding Limited is a wholly-owned subsidiary by Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership). Zhijun Sihang Holding Limited, a British Virgin Islands company, holds 536,000 Class A ordinary shares and 247,900 Class B ordinary shares. In addition, Lei Luo holds 70,700 Class A ordinary shares for the benefit of Zhijun Sihang Holdings Limited. Jiaxing Zhijun Investment Management Co., Ltd. is the general partner of Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership) and Mr. Feng Guo is the controlling shareholder and a member of the three-person investment committee of Jiaxing Zhijun Investment Management Co., Ltd.

     

    (3)The calculations in the table below are based on 12,055,760 ordinary shares (including 9,192,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

    Page 4 of 12

     

     

    SCHEDULE 13G

     

    CUSIP No. Class A: G0393E107; Class B: N/A  

     

    1

    Names of Reporting Persons

    Jiaxing Zhijun Investment Management Co., Ltd.
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒
    3

    Sec Use Only

     
    4

    Citizenship or Place of Organization

    China

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    6 Shared Voting Power
    606,700 shares of Class A Ordinary Shares
    7 Sole Dispositive Power

    536,000 shares of Class A Ordinary Shares (1)

    247,900 shares of Class B Ordinary Shares (1)

    8 Shared Dispositive Power
    606,700 shares of Class A Ordinary Shares

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    606,700 shares of Class A Ordinary Shares

    247,900 shares of Class B Ordinary Shares

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    ☐
    11 Percent of class represented by amount in row (9)

    6.60% of Class A Ordinary Shares

    8.66% of Class B Ordinary Shares 

    12

    Type of Reporting Person (See Instructions)

    CO

      

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Zhijun Sihang Holding Limited is a wholly-owned subsidiary by Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership). Jiaxing Zhijun Investment Management Co., Ltd. is the general partner of Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership) and Mr. Feng Guo is the controlling shareholder and a member of the three-person investment committee of Jiaxing Zhijun Investment Management Co., Ltd. Zhijun Sihang Holding Limited holds 536,000 Class A ordinary shares and 247,900 Class B ordinary shares of the Company. In addition, Lei Luo holds 70,700 Class A ordinary shares for the benefit of Zhijun Sihang Holdings Limited.

     

    (3)The calculations in the table below are based on 12,055,760 ordinary shares (including 9,192,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

    Page 5 of 12

     

     

    SCHEDULE 13G

     

    CUSIP No. Class A: G0393E107; Class B: N/A  

     

    1

    Names of Reporting Persons

    Lei Luo
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒
    3

    Sec Use Only

     
    4

    Citizenship or Place of Organization

    China

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5

    Sole Voting Power

    0
    6

    Shared Voting Power

    70,700 shares of Class A Ordinary Shares (2)
    7

    Sole Dispositive Power

    0
    8

    Shared Dispositive Power

    70,700 shares of Class A Ordinary Shares (2)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    70,700 shares of Class A Ordinary Shares
    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    ☐
    11

    Percent of class represented by amount in row (9)

    0.77% of Class A Ordinary Shares
    12

    Type of Reporting Person (See Instructions)

    IN

      

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Representing Class A ordinary shares held for the benefit of Zhijun Sihang Holdings Limited.

     

    (3)The calculations in the table below are based on 12,055,760 ordinary shares (including 9,192,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

    Page 6 of 12

     

      

    Item 1.  

     

    (a) Name of Issuer: AnPac Bio-Medical Science Co., Ltd.

     

    (b) Address of Issuer’s Principal Executive Offices: 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006, People’s Republic of China

     

    Item 2.  

     

    (a) Name of Person Filing:

     

      (1) Feng Guo
      (2) Zhijun Sihang Holding Limited
      (3) Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership)
      (4) Jiaxing Zhijun Investment Management Co., Ltd.
      (5) Lei Luo

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    113-7, No.100, Zhuyuan Road, Nanhu District, Jiaxing, Zhejiang Province, P.R. China.

     

    (c) Citizenship:

     

      (1) Feng Guo: China
      (2) Zhijun Sihang Holding Limited: British Virgin Islands
      (3) Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership): China
      (4) Jiaxing Zhijun Investment Management Co., Ltd.: China
      (5) Lei Luo: China

     

    (d) Title and Class of Securities:

     

    Class A Ordinary Shares, par value $0.01 per ordinary share

    Class B Ordinary Shares, par value $0.01 per ordinary share

     

    (e) CUSIP No.:

     

    Class A Ordinary Shares: G0393E107

    Class B Ordinary Shares: N/A  

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act;
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
      (j) ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________

     

    Page 7 of 12

     

     

    Item 4. Ownership

      

    The percentages of ownership set forth below are based on 12,055,760 ordinary shares (including 9,192,660 Class A ordinary shares and 2,863,100 Class B ordinary shares) outstanding as of February 10, 2021.

     

       Name   Class A (1)   Class B (1) 
    (a) Amount Beneficially Owned  Feng Guo (2)   606,700    247,900 
       Zhijun Sihang Holding Limited (2)   606,700    247,900 
    (b) Percentage of class  Feng Guo   6.60%   8.66%
       Zhijun Sihang Holding Limited   6.60%   8.66%
    (c) Number of shares as to which the person has:             
    (i) Sole power to vote or to direct the vote:             
       Feng Guo   0    0 
       Zhijun Sihang Holding Limited   606,700    247,900 
    (ii) Shared power to vote or to direct the vote:             
       Feng Guo   606,700    247,900 
       Zhijun Sihang Holding Limited   606,700    247,900 
    (iii) Sole power to dispose or to direct the disposition of:             
       Feng Guo   0    0 
       Zhijun Sihang Holding Limited   606,700    606,700 
    (iv) Shared power to dispose or to direct the disposition of:             
       Feng Guo   606,700    247,900 
       Zhijun Sihang Holding Limited   606,700    247,900 

     

    (1)Each share of Class A Ordinary Shares is entitled to one vote per share, whereas each share of Class B Ordinary Share is entitled to ten (10) votes per share.

     

    (2)Represents (i) 536,000 Class A ordinary shares and 247,900 Class B ordinary shares held by Zhijun Sihang Holding Limited, a British Virgin Islands company, which is wholly owned by Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership), and (ii) 70,700 Class A ordinary shares held by Mr. Lei Luo for the benefit of Zhijun Sihang Holdings Limited. The general partner of Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership) is Jiaxing Zhijun Investment Management Co., Ltd. Mr. Feng Guo is the controlling shareholder and a member of the three-person investment committee of Jiaxing Zhijun Investment Management Co., Ltd. Mr. Guo disclaims any beneficial ownership with respect to these shares. The registered address of Zhijun Sihang Holding Limited is 113-7, No.100, Zhuyuan Road, Nanhu District, Jiaxing, Zhejiang Province, P.R. China..

     

    Page 8 of 12

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not Applicable.

     

    Item 8. Identification and classification of members of the group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

    Exhibit A – Joint Filing Agreement
    Exhibit B – Shareholding Entrustment Agreement

     

    Page 9 of 12

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021

     

    Feng Guo

     

    /s/ Feng Guo

     
    Feng Guo  

      

    Zhijun Sihang Holding Limited 

     

    /s/ Feng Guo  

    Feng Guo

    president

     

     

    Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership)

     

    /s/ Feng Guo  

    Feng Guo

    president

     

     

    Jiaxing Zhijun Investment Management Co., Ltd.

     

    /s/ Feng Guo  

    Feng Guo

    legal representative

     

     

    Lei Luo

     

    /s/ Lei Luo  
    Lei Luo  

     

    Page 10 of 12

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that he, she or it knows or has reason to believe that such information is not accurate. The undersigned each expressly authorize each other to file any and all amendments to such statement on their behalf. The undersigned agree that this joint filing agreement may be signed in counterparts.

     

    Dated: February 12, 2021

     

    Feng Guo

     

    /s/ Feng Guo

     
    Feng Guo  

      

    Zhijun Sihang Holding Limited 

     

    /s/ Feng Guo  

    Feng Guo

    president

     

     

    Jiaxing Zhijun Sihang Investment Partnership Enterprises (Limited Partnership)

     

    /s/ Feng Guo  

    Feng Guo

    president

     

     

    Jiaxing Zhijun Investment Management Co., Ltd.

     

    /s/ Feng Guo  

    Feng Guo

    legal representative

     

     

    Lei Luo

     

    /s/ Lei Luo  
    Lei Luo  

     

    Page 11 of 12

     

     

    EXHIBIT B

     

    Shareholding Entrustment Agreement

     

    Party A: Jiaxing Zhijun Sihang Investment Partnership (hereinafter referred to as “Party A”)

     

    Registration number: 91330402MA28BR6G06

     

    Party B: Luo Lei (hereinafter referred to as “Party B”)

     

    ID number: 371302198404301839

     

    Given:

     

    Party A intends to hold 70700 shares of Anpac Bio-Medical Science Co., Ltd (referred to as “Anpac” in this agreement) (referred to as “Target Equity” in this agreement) directly or through an entity controlled by Party A.

     

    After friendly negotiation, the two parties reached the following agreement:

     

    1. Party A takes the target equity it owns as “holding equity” through this agreement, and signs the contract through Party B, directly registers it under the name of Party B, and entrusts Party B to hold it on its behalf in the name of Party B, related benefits, etc. The rights are enjoyed by Party A.

     

    2. The scope of Party A entrusting Party B to hold the target equity and exercise its rights includes: being named on the Anpac investor roster; participating in corresponding activities as an Anpac investor; collecting dividends based on the proportion of Anpac equity held by Party A; Party A grants from time to time Party B’s rights of other equity holders.

     

    3. The period of time for Party B to hold equity on behalf of this agreement is from the date of establishment of this agreement to the day when Party A becomes a named holder.

     

    4. As the dormant holder, Party A has the obligation to make capital contributions in a timely manner (if any) in accordance with the relevant agreement of the target equity. Party A has the right to know about Anpac’s investment, and has actual shareholder rights and all investment income such as income distribution and other income from Anpac, and bears all investment risks. Party B does not enjoy the target equity and other rights and interests and income right or disposal right held on behalf of Party A (including but not limited to the transfer of target equity, pledge, etc.).

     

    5. Party B shall not carry out any behavior that may damage the interests of Party A, and Party B promises to unconditionally transfer any income it receives due to the equity holdings to Party A.

     

    6. Both parties to the agreement shall have the obligation to keep confidential any commercial information of the other party that they contact or learn during the performance of this agreement, unless they have obtained prior written authorization from the other party.

     

    7. Any disputes arising from or related to this agreement shall be resolved through negotiation. If the negotiation fails, either party shall bring a lawsuit to the people’s court where Party A is domiciled.

     

    8. Without the prior written consent of the other party, neither party shall transfer its rights and obligations under this agreement to any third party.

     

    9. This agreement is in duplicate, and both parties hold one copy, and each agreement has the same legal effect. If both parties add to this agreement afterwards, they shall sign a written supplementary agreement.

     

    10. This agreement will come into effect on the day when both parties sign or seal.

     

    Party A (seal): /s/ Feng Guo                                    Party B (signature): /s/ Lei Luo

     

    Legal representative/authorized representative:

     

    October 2019 October 2019

     

     

    Page 12 of 12

     

    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    SEC Filings

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care